BIOMAT Database Logo BIOMAT Database Logo

1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. 2008

Peng Zhan, and Xinyong Liu, and Yuan Cao, and Yan Wang, and Christophe Pannecouque, and Erik De Clercq
Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, Jinan, Shandong 250012, PR China.

A novel series of 1,2,3-thiadiazole thioacetanilide (TTA) derivatives have been designed, synthesized and evaluated for its anti-HIV activities in MT-4 cells. Some derivatives proved to be highly effective in inhibiting HIV-1 replication at nanomolar concentrations. Among them, 2-[4-(2,4-dichlorophenyl)-1,2,3-thiadiazol-5-ylthio]-N-(2-nitrophenyl)acetamide 7d2 was identified as the most promising compound (EC(50)=0.059+/-0.02 microM, CC(50)>283.25 microM, SI>4883). The structure-activity relationship (SAR) of these novel structural congeners is discussed.

UI MeSH Term Description Entries
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001681 Biological Assay A method of measuring the effects of a biologically active substance using an intermediate in vivo or in vitro tissue or cell model under controlled conditions. It includes virulence studies in animal fetuses in utero, mouse convulsion bioassay of insulin, quantitation of tumor-initiator systems in mouse skin, calculation of potentiating effects of a hormonal factor in an isolated strip of contracting stomach muscle, etc. Bioassay,Assay, Biological,Assays, Biological,Biologic Assay,Biologic Assays,Assay, Biologic,Assays, Biologic,Bioassays,Biological Assays
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013830 Thiadiazoles Heterocyclic compounds composed of a five-membered heterocyclic ring which contains one sulfur and two nitrogen atoms. Thiadiazole
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Peng Zhan, and Xinyong Liu, and Yuan Cao, and Yan Wang, and Christophe Pannecouque, and Erik De Clercq
2D, 3D-QSAR and docking studies of 1,2,3-thiadiazole thioacetanilides analogues as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
June 2012, Organic and medicinal chemistry letters,
Peng Zhan, and Xinyong Liu, and Yuan Cao, and Yan Wang, and Christophe Pannecouque, and Erik De Clercq
Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant.
May 2006, Bioorganic & medicinal chemistry letters,
Peng Zhan, and Xinyong Liu, and Yuan Cao, and Yan Wang, and Christophe Pannecouque, and Erik De Clercq
Difluoromethylbenzoxazole pyrimidine thioether derivatives: a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
December 2011, Journal of medicinal chemistry,
Peng Zhan, and Xinyong Liu, and Yuan Cao, and Yan Wang, and Christophe Pannecouque, and Erik De Clercq
Aryl Substituted Benzimidazolones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.
February 2019, ACS medicinal chemistry letters,
Peng Zhan, and Xinyong Liu, and Yuan Cao, and Yan Wang, and Christophe Pannecouque, and Erik De Clercq
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
February 2004, Journal of medicinal chemistry,
Peng Zhan, and Xinyong Liu, and Yuan Cao, and Yan Wang, and Christophe Pannecouque, and Erik De Clercq
Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs).
January 2008, Bioorganic & medicinal chemistry letters,
Peng Zhan, and Xinyong Liu, and Yuan Cao, and Yan Wang, and Christophe Pannecouque, and Erik De Clercq
Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
July 2010, Journal of medicinal chemistry,
Peng Zhan, and Xinyong Liu, and Yuan Cao, and Yan Wang, and Christophe Pannecouque, and Erik De Clercq
Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
February 2017, Bioorganic chemistry,
Peng Zhan, and Xinyong Liu, and Yuan Cao, and Yan Wang, and Christophe Pannecouque, and Erik De Clercq
Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase.
September 2006, Bioorganic & medicinal chemistry letters,
Peng Zhan, and Xinyong Liu, and Yuan Cao, and Yan Wang, and Christophe Pannecouque, and Erik De Clercq
Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors: A Combinatorial Approach.
December 2017, Biochemistry. Biokhimiia,
Copied contents to your clipboard!